

UNITED STATE DEPARTMENT OF COMMERCE Patent and Trademark Office

NOTICE OF ALLOWANCE AND ISSUE FEE DUE

HM12/0713

JOHN P WHITE COOPER & DUNHAM 1185 AVENUE OF THE AMERICAS NEW YORK NY 10036

APPLIC	CATION NO.	ILING DATE	TOTAL CLAIMS	EXAMINER ANI	D GROUP ART UNIT	DATE MAILED
	09/287,884	04/07/99	014	GOLDBERG, J	16	14 07/13/01
First Named Applicant	WANEBO.		35 U	SC 154(b) te	rm ext. = 0	Days.

TITLE OF

COMBINATIONS OF CERAMIDE AND CHEMOTHERAPEUTIC AGENTS FOR INDUCING

	ď.	ATTYS	DOCKET NO.	CLASS-SU	BCLASS	BATCH NO.	APPLN.	TYPE	SMALL	ENTITY	FEE DUE		DATE DUE
		4	584 6 37J	EEDIO ZEEM	C 1.4	-449.000	J08	HTTI	777	YES	\$620.0	ni.	10/15/01
1	٠.٠		. acedas/i	FEW/E.M	0147	-445.000	200	UTIL	TIL	312.00	*0%0.0	i, i	10,12,01

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED.

THE ISSUE FEE MUST BE PAID WITHIN <u>THREE MONTHS</u> FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. <u>THIS STATUTORY PERIOD CANNOT BE EXTENDED.</u>

HOW TO RESPOND TO THIS NOTICE:

- I. Review the SMALL ENTITY status shown above.
 If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:
 - A. If the status is changed, pay twice the amount of the FEE DUE shown above and notify the Patent and Trademark Office of the change in status, or
 - B. If the status is the same, pay the FEE DUE shown above.
- If the SMALL ENTITY is shown as NO:
- A. Pay FEE DUE shown above, or
- B. File verified statement of Small Entity Status before, or with, payment of 1/2 the FEE DUE shown above.
- 11. Part B-Issue Fee Transmittal should be completed and returned to the Patent and Trademark Office (PTO) with your ISSUE FEE. Even if the ISSUE FEE has already been paid by charge to deposit account, Part B Issue Fee Transmittal should be completed and returned. If you are charging the ISSUE FEE to your deposit account, section "4b" of Part B-Issue Fee Transmittal should be completed and an extra copy of the form should be submitted.
- Ill. All communications regarding this application must give application number and batch number.

 Please direct all communications prior to issuance to Box ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PATENT AND TRADEMARK OFFICE COPY

	Application No.	Applicant(s)	
	09/287,884	WANEBO ET AL.	
Notice of Allowability	Examiner	Art Unit	
	Jerome D Goldberg	1614	
The MAILING DATE of this communication appeal claims being allowable, PROSECUTION ON THE MERITS IS nerewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT Rof the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this ap or other appropriate communication IGHTS. This application is subject to	plication. If not includ will be mailed in due	ed course. THIS
 The drawings filed on are accepted by the Examine Acknowledgment is made of a claim for foreign priority und a) ☐ All b) ☐ Some* c) ☐ None of the: 			
1. ☐ Certified copies of the priority documents have	e been received.		
2. Certified copies of the priority documents have		·	
 Copies of the certified copies of the priority do International Bureau (PCT Rule 17.2(a)). 			ition from the
* Certified copies not received: 5. Acknowledgment is made of a claim for domestic priority u (a) The translation of the foreign language provisional a 6. Acknowledgment is made of a claim for domestic priority u	application has been received.	ional application).	
Applicant has THREE MONTHS FROM THE "MAILING DATE" o below. Failure to timely comply will result in ABANDONMENT of	f this communication to file a reply c this application. THIS THREE-MO	omplying with the required in NOT NOT	uirements noted EXTENDABLE.
7. A SUBSTITUTE OATH OR DECLARATION must be subr INFORMAL PATENT APPLICATION (PTO-152) which gives rea	mitted. Note the attached EXAMINEF son(s) why the oath or declaration is	R'S AMENDMENT or deficient.	NOTICE OF
 8. ☐ CORRECTED DRAWINGS must be submitted. (a) ☐ including changes required by the Notice of Draftspe 1) ☐ hereto or 2) ☐ to Paper No. 5. (b) ☐ including changes required by the proposed drawing (c) ☐ including changes required by the attached Examine 	correction filed, which has t	een approved by the	Examiner.
Identifying indicia such as the application number (see 37 CFR of each sheet. The drawings should be filed as a separate pape	1.84(c)) should be written on the draw r with a transmittal letter addressed to	ngs in the top margin (the Official Draftspers	not the back) on.
9. DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT FOR	osit of BIOLOGICAL MATERIAL THE DEPOSIT OF BIOLOGICAL MA	must be submitted. ATERIAL.	Note the
Attachment(s)			
 1 ☐ Notice of References Cited (PTO-892) 3 ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 5 ☑ Information Disclosure Statements (PTO-1449), Paper No. 7 ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material 	4☑ Interview Sumn 10 6☑ Examiner's Am	nal Patent Application hary (PTO-413), Pape endment/Comment tement of Reasons for Jerome D Goldbe Primary Examiner Art Unit: 1614	r No

D

Application/Control Number: 09/287,884

Art Unit: 1614

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Alan J. Morrison on July 12, 2001.

	The application has been amended as follows:	
	In claim 30, line 11 after the term "cell" insert, the apoptosis being greater than the apoptosis caused	<u></u>
<u>p'</u>	in the cell by either paclitaxel alone or C_6 -ceramide alone	
	In claim 31, line 9 after the term "concomitantly", insert, wherein the resulting apoptosis in the	
D2-	subject's cancer cells is greater than the apotosis caused by administering either paclitaxel alone or C_6 -ceramide	
•	alone	

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jerome D Goldberg whose telephone number is 703-308-4606.

The examiner can normally be reached on 9:30 am to 3:30pm Mon-Thur.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel can be reached on 703-308-4725. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4556 for regular communications and 703-308-7924 for After Final communications.

Application/Control Number: 09/287,884

Art Unit: 1614

Page 3

Any inquiry of a general nature or relating to the status of this application or proceeding

should be directed to the receptionist whose telephone number is 703-308-1235.

Jerome D Goldberg Primary Examiner Art Unit 1614

July 12, 2001